Fentanyl is used to treat severe pain, particularly in cancer patients and people with chronic pain conditions. It can also be used before surgery to help patients relax and reduce anxiety.[2] Duragesic is currently approved and in use across 97 indications[4].[1]
Duragesic is one of 1487 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
1931 competitors in COVID-19
Duragesic
Spikevax
Bnt162b2
Biaxin
Singulair
Statin
Olokizumab
Antithrombin-III
Conventional
Blood Taken
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
SUBLIMAZE PRESERVATIVE FREE
NDA NDA016619
Jan 12, 1985
FENTANYL CITRATE
NDA NDA019115
Aug 7, 1990
DURAGESIC-100
NDA NDA019813
Oct 30, 1995
FENTANYL
NDA NDA020195
Nov 4, 1998
ACTIQ
NDA NDA020747
May 22, 2006
IONSYS
NDA NDA021338
Sep 25, 2006
FENTORA
NDA NDA021947
Jul 16, 2009
ONSOLIS
NDA NDA022266
Jan 7, 2011
ABSTRAL
NDA NDA022510
Jun 30, 2011
LAZANDA
NDA NDA022569
Jan 4, 2012
SUBSYS
NDA NDA202788
Jan 20, 2023
FENTANYL CITRATE
NDA NDA019101
Feb 8, 2023
FENTANYL CITRATE
NDA NDA215870
Sources
Details
Patent Cliff
Jan 25, 2027
Earliest patent expiration — generic entry possible after this date